Global Anticoagulant Registry in the FIELD observing treatment and outcomes in patients with treated acute Venous Thromboembolic Events in the real world.
The study objectives are to describe acute, sub-acute and extended duration of anticoagulation management, clinical and economic outcomes in patients with treated acute VTE (DVT and PE) in the real-world setting.
Global, prospective, observational, multi-centre VTE registry to be conducted in sequential cohorts.
In order to observe temporal trends in management of VTE a minimum of 2 cohorts will be recruited. Recruitment into the second (or subsequent cohorts) will commence when recruitment is completed into the first or previous cohort. It is estimated that each cohort will take approximately 9 months to recruit. Potential patients must be assessed for eligibility within 30 days of their acute VTE diagnosis.
5000 consecutive unselected patients treated for acute VTE and followed prospectively for a minimum of 36 months
A further 5000 consecutive unselected patients treated for acute VTE and followed prospectively for a minimum of 36 months
This is a study looking at incidence and risk factors for poor ankle functional recovery, and the development and progression of post-traumatic ankle osteoarthritis after significant ankle ligament injury.
SALI study - Significant Ankle Ligament Injury
The study with PP100-01 in combination with NAC is designed to determine safety and tolerability of PP100-01 when co-administered with NAC as compared to the 12-hr NAC treatment regime for patients that come to the hospital after an overdose of paracetamol/acetaminophen.
A Randomised Open Label Exploratory, Safety and Tolerability Study with PP100-01 in Patients Treated with the 12-hour Regimen of N-Acetylcysteine for Paracetamol/Acetaminophen Overdose
Patients commonly present to the Emergency Department with epistaxsis (nose bleed). Standard first aid measures such as applying pressure can often stem bleeding however in more severe cases of epistaxsis further treatment is required.
Novel Use of Tranexamic Acid to Reduce the Need for Nasal Packing